Please ensure Javascript is enabled for purposes of website accessibility

Why Emergent BioSciences Stock Is Falling Today

By Keith Speights – Oct 13, 2020 at 12:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Blame it on Johnson & Johnson's pause of a late-stage study of its coronavirus vaccine candidate.

What happened

Shares of Emergent BioSolutions (EBS 4.50%) were falling 10.3% as of 11:45 a.m. EDT on Tuesday. The drop came after Johnson & Johnson announced that it had paused its late-stage study of coronavirus vaccine candidate JNJ-78436735 because of an unexplained illness with one participant. In July, Emergent BioSolutions signed a five-year deal with J&J to manufacture its lead COVID-19 vaccine candidate.

So what

Today's sell-off of Emergent BioSolutions could very well be an overreaction. There's a good chance that Johnson & Johnson's pause of its late-stage study will only be temporary, with no effect on Emergent's manufacturing of JNJ-78436735.

Vaccine bottles

Image source: Getty Images.

Adverse reactions in clinical studies aren't out of the ordinary. So far, there haven't been enough details released to know what to make of the issue that caused J&J to pause its phase 3 study.

Sure, it's possible that the investigation of the unexplained illness with one participant in J&J's clinical trial of its coronavirus vaccine candidate could lead to bigger worries about JNJ-78436735. If that happened, Emergent's manufacturing contract would potentially be jeopardized. However, it's way too early to assume that the situation will deteriorate in such a negative way for both companies.

Now what

Emergent BioSolutions' shares could remain volatile until more information is available about the potential safety issue in J&J's late-stage study of JNJ-78436735. However, the healthcare stock could also enjoy a big rebound if the study resumes quickly. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Emergent BioSolutions Stock Quote
Emergent BioSolutions
$12.30 (4.50%) $0.53
Johnson & Johnson Stock Quote
Johnson & Johnson
$178.00 (1.08%) $1.91

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.